Please ensure Javascript is enabled for purposes of website accessibility

A Painful Letter from the FDA

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Remoxy needs more work.

Ouch! It didn't come as a surprise to me, but it's painful to watch nonetheless.

The Food and Drug Administration smacked down King Pharmaceuticals (NYSE:KG) and Pain Therapeutics (NASDAQ:PTIE) today with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone. Shares are trading down over 6% and nearly 19%, respectively, as I write.

The good news is that the companies, which designed the drug using DURECT's (NASDAQ:DRRX) delivery system, aren’t being required to do more clinical studies. (DURECT is down almost 21% so far today.) Anything the FDA needs should be able to be carried out in the lab, which will likely be faster than a clinical trial.

The companies didn't say what data the agency was looking for, but it almost certainly has to do with the "abuse-resistant" part of Remoxy. From the documents provided to the FDA advisory panel that reviewed Remoxy, it's pretty clear that the FDA has no idea how hard a drug abuser would work to get the active ingredient out of Remoxy and into a form that can be abused (in case you're wondering, I haven't a clue either). Pain Therapuetics showed that very little of the active ingredient was extracted by leaving the pills in solvents for an hour, but the FDA likely thinks that longer tests are needed.

Alpharma (NYSE:ALO), which is being acquired by King, also has an abuse-resistant drug, Embeda, up for review by the agency. King could get a double whammy if the FDA has decided to take a hard line on the definition of abuse resistance. Companies farther behind in development of "tamper-resistant" and abuse-deterrent methodologies, like Cephalon (NASDAQ:CEPH) and Flamel Technologies (NASDAQ:FLML), should have plenty of time to get their acts together once the FDA finally decides what it takes to be "abuse-resistant."

Are today's huge drops in Pain and DURECT justified? Somewhat, but until we know more about how long it will take the companies to respond to the FDA, it's difficult to know how much lower the value should be today than it was yesterday. Hang in there, investors; I know it's painful, but Remoxy should get on the market, eventually.

Pain-free Foolishness:

Let us know what you think in Motley Fool CAPS. Make an out- or underperform call on these companies; post a pitch about whether you think Remoxy will ever make it to market. It's free, it’s fun, and it’s Foolish!

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DURECT Corporation Stock Quote
DURECT Corporation
DRRX
$0.78 (11.43%) $0.08
Avadel Pharmaceuticals plc Stock Quote
Avadel Pharmaceuticals plc
FLML

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.